Glen Eagle Resources Acquires Highly Prospective Lithium Properties

 

(TheNewswire)

 
     
  Glen Eagle Resources Inc. 
          
 

Glen Eagle Resources Inc. (the " Corporation ") (TSXV:GER) is pleased to announce that it has acquired by map designation 120 mining claims in three groups in the Lebel-sur-Quevillon area, Northwestern Quebec

 

  The 3 groups of claims are prospective for lithium. On the Lessard property, pegmatites have been recognized on the property in close association with a lake-bottom lithium anomaly of 61 ppm of Lithium. The property is underlain by the Lichen Pluton, a tonalite-monzodiorite intrusive of Archean Age.  

 

  The Périgny property is characterized by a 7-km long lake-bottom lithium anomalies varying from 19 to 26 ppm of Lithium, and is underlain with the granodiorite of the Mountain Pluton.  

 

  The Nicobi property is characterized by a 1-km long lake-bottom lithium anomalies varying from 33 to 45 ppm of Lithium, and is underlain by the Lichen Pluton, a tonalite-monzodiorite intrusive of Archean Age.  

 

  Quebec's Government LIDAR survey shows that the properties bear northeast-trending elongated crests that may be indicative of the presence of pegmatites.  

 

  All three properties are easily accessible from logging roads and trails originating from Provincial Highway 113. The Company intends to mobilize field crews this summer to do geological reconnaissance and verify the elongated crests on the properties.  

 

  Qualified Person  

 

  Mr. Gilles Laverdière, P.Geo, consultant geologist and qualified person under NI 43-101 has read and approved this press release.  

 

  Securities Monetization Update  

 

  Further to its May 10, 2023 press release, the Corporation is also please to announces it has closed the previously announced disposition of 2,700,000 common shares of First Phosphate Corp.  

 

  ABOUT GLEN EAGLE RESOURCES INC.  

 

  Glen Eagle Resources Inc. is a small producer and an exploration company of precious metals in Canada and the Central America area.  

 

  For more information, please contact:  

 

  Karl Trudeau
President
1-819-440-8495
 

 

  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.  

 

  FORWARD LOOKING STATEMENTS:  

 

  This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Corporation. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Corporation does not assume any obligation to update or revise them to reflect new events or circumstances. All the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR in Canada (available at    WWW.SEDAR.COM    ).  

 

Copyright (c) 2023 TheNewswire - All rights reserved.

 

News Provided by TheNewsWire via QuoteMedia

TMO
The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×